Valuation: Lineage Cell Therapeutics, Inc.

Market Cap 268M 231M 217M 198M 372M 25.63B 377M 2.55B 997M 12.84B 1.01B 985M 42.72B P/E 2026 *
-15.8x
P/E 2027 * -10.2x
Enterprise Value 268M 231M 217M 198M 372M 25.63B 377M 2.55B 997M 12.84B 1.01B 985M 42.72B EV / Sales 2026 *
17.6x
EV / Sales 2027 * 15.9x
Free-Float
95.14%
Yield 2026 *
-
Yield 2027 * -
1 day-0.93%
1 week-6.19%
Current month-1.85%
1 month-8.62%
3 months-15.20%
6 months-36.90%
Current year-36.53%
1 week 1.05
Extreme 1.05
1.13
1 month 1
Extreme 1
1.18
Current year 1
Extreme 1
1.98
1 year 1
Extreme 1
2.09
3 years 0.37
Extreme 0.3651
2.09
5 years 0.37
Extreme 0.3651
2.8
10 years 0.37
Extreme 0.3651
4
Manager TitleAgeSince
Chief Executive Officer 54 16/09/2018
Director of Finance/CFO 50 13/11/2022
Chief Operating Officer - 30/11/2010
Director TitleAgeSince
Director/Board Member 60 30/06/2009
Director/Board Member 68 10/04/2014
Chairman 60 26/04/2024
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Free

Director

125,000 0.0501%
01/07/26
Broadwood Capital, Inc.
FreeCompany 125,000 0.0501%
01/07/26 Free

Director

125,000 0.0501%
Change 5-day change 1-year change 3-year change Capi.($)
-0.93%-6.19%-11.67%-23.19% 268M
+0.68%-2.28%+2.16%+19.70% 48.84B
+4.07%+2.43%+483.70%+623.80% 45.44B
+4.33%+0.98%+12.80%+88.53% 41.22B
+1.94%-0.31%+26.24%+12.62% 39.71B
-0.50%0.00%+20.60%+60.49% 32.6B
-0.44%-3.22% - - 16.25B
+3.22%-0.88%+30.42%+135.47% 16.67B
-0.62%-0.06%+3.46%+27.74% 14.08B
+2.35%+3.48%+82.95%+43.41% 13.68B
Average +1.41%-0.25%+72.30%+109.84% 26.88B
Weighted average by Cap. +1.96%+0.05%+103.02%+153.13%

Financials

2026 *2027 *
Net sales 15.19M 13.12M 12.31M 11.21M 21.07M 1.45B 21.37M 144M 56.53M 728M 57.04M 55.81M 2.42B 16.83M 14.53M 13.63M 12.42M 23.35M 1.61B 23.67M 160M 62.63M 806M 63.2M 61.83M 2.68B
Net income -22.64M -19.55M -18.34M -16.7M -31.4M -2.16B -31.84M -215M -84.23M -1.08B -85M -83.16M -3.61B -34.44M -29.73M -27.89M -25.41M -47.77M -3.29B -48.43M -327M -128M -1.65B -129M -127M -5.49B
Net Debt - -
Logo Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
75
Date Price Change Volume
17/08/26 US$1.060 -0.93% 795,388
14/08/26 US$1.070 +0.94% 1,129,385
13/08/26 US$1.060 -3.64% 957,588
12/08/26 US$1.100 -1.79% 698,007
11/08/26 US$1.120 -0.88% 763,807
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.060USD
Average target price
5.500USD
Spread / Average Target
+418.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LCTX Stock